Trials / Completed
CompletedNCT00297258
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists and to characterize the pharmacokinetics of pazopanib in this subject population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pazopanib | oral tablet |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2006-02-28
- Last updated
- 2016-02-03
- Results posted
- 2010-01-06
Locations
16 sites across 5 countries: Belgium, France, Hungary, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT00297258. Inclusion in this directory is not an endorsement.